Medable reported independent modeling results suggesting its AI-assisted clinical monitoring software can reduce trial costs by improving how monitors handle documentation and site variability. The tool, Medable’s Clinical Monitoring Agent, checks for missing documentation fields, flags discrepancies in trial paperwork, and tracks multiple variables across sites; Tufts Center for the Study of Drug Development researchers benchmarked the impact using real-world oncology development data.